A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Trial Profile

A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs AZD 5363 (Primary) ; Vistusertib (Primary) ; Olaparib
  • Indications Adenocarcinoma; Breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2014 Status changed from not yet recruiting to recruiting, as reported by M.D. Anderson Cancer Center.
    • 12 Nov 2014 Planned primary completion date changed from 1 Oct 2020 to 1 Nov 2020, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top